Across multiple preclinical studies, interventions targeting AngII signaling, whether through pharmacologic blockade or genetic disruption, have been consistently associated with reduced lesion size, improved plaque composition, and attenuation of disease progression in atherosclerosis. Here, AGT is linked to atherosclerosis.